Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy

Blood (2025) 146 (24): 2945–2962.

https://doi.org/10.1182/blood.2025028441

Published: 2025

Includes: Supplemental data

Journal Articles

Brentuximab vedotin (Bv)+AVD efficacy is influenced by interim PET, age, ECOG performance status and CIRS-g in previously untreated patients with stage IV classical Hodgkin lymphoma: An Italian real-life multicentric study

Blood (2025) 146 (Supplement 1): 5402.

https://doi.org/10.1182/blood-2025-5402

Published: 2025

Journal Articles

The treatment of transplant eligible primary plasmacell leukemia patients: An italian real-life Study

Blood (2025) 146 (Supplement 1): 3977.

https://doi.org/10.1182/blood-2025-3977

Published: 2025

Journal Articles

The prognostic value for survival of frailty and patient-reported outcomes in relapsed/refractory multiple myeloma: Results from a prospective multicenter observational study

Fabio Efficace, Gianluca Gaidano, Pasquale Niscola, Serena Puglia, Francesco Sparano, Katia Codeluppi, Elisabetta Antonioli, Catello Califano, Lajos Floro, Ombretta Annibali, Claudio Fozza, Agostino Tafuri, Patrizio Mazza, Leonardo Potenza, Marco Vignetti, Michele Cavo, Maria Teresa Petrucci

Blood (2025) 146 (Supplement 1): 138.

https://doi.org/10.1182/blood-2025-138

Published: 2025

Journal Articles

Post-transplant lymphoproliferative disorders in adult transplant recipients: Preliminary results of the multicenter italian FIL_PTLD study

Blood (2025) 146 (Supplement 1): 1890.

https://doi.org/10.1182/blood-2025-1890

Published: 2025

Journal Articles

Lessons from the IELSG45 trial: The impact of patient fitness on dropout rate in primary central nervous system lymphoma (PCNSL) studies

Blood (2025) 146 (Supplement 1): 1908.

https://doi.org/10.1182/blood-2025-1908

Published: 2025

Journal Articles

Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2024-207886

Published: 2024

Journal Articles

Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study

Blood (2024) 144 (Supplement 1): 3020.

https://doi.org/10.1182/blood-2024-207163

Published: 2024

Journal Articles

Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Blood (2024) 144 (Supplement 1): 5153.

https://doi.org/10.1182/blood-2024-204021

Published: 2024

Journal Articles

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi, Giovanni Reddiconto, Paola Stefanoni, Jacopo Micozzi, Silvia Mangiacavalli, Elena Zamagni, Massimo Offidani, Anna Furlan, Gabriele Buda, Sr., Flavia Lotti, Carmine Liberatore, Antonio Lazzaro, Roberta Della Pepa, Giuseppe Bertuglia, Emiliano Barbieri, Concetta Conticello, Claudio De Magistris, Lorenzo De Paoli, Velia Bongarzoni, Anna Maria Cafro, Anna Mele, Pietro Benvenuti, Claudio Cerchione, Cirino Botta, Elisabetta Antonioli, Nicola Sgherza, Sara Aquino, Giuseppe Mele, Gregorio Barila, Salvatore Palmieri, Ombretta Annibali, Rosario Bianco, Massimiliano Arangio Febbo, Gloria Margiotta Casaluci, Angela Rago, Raffaele Fontana, Francesca Farina, Ernesto Vigna, Antonella Bruzzese, Catello Califano, Angela Amendola, Daniela Roccotelli, Alessandra Lombardo, Annalisa Citro, Giuseppina Uccello, Renato Zambello, Alessandro Maggi, Santo Neri, Michele Monachesi, Alessandro Gozzetti, Vittorio Montefusco, Marino Brunori, Nicola Di Renzo, Marta Coscia, Valerio De Stefano, Antonino Neri, Francesco Di Raimondo, Fortunato Morabito, Pellegrino Musto, Massimo Gentile

Blood (2024) 144 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2024-206008

Published: 2024

Journal Articles

Incidence of Infections and Prophylaxis Practice, in Two Cohorts of Patients of Autoimmune Disorders of Hematological Interest or Non-Hodgkin Lymphoma Treated with Rituximab

Blood (2024) 144 (Supplement 1): 5395.

https://doi.org/10.1182/blood-2024-198784

Published: 2024

Journal Articles

T Cell Ig and ITIM Domains (TIGIT) Expression in Multiple Myeloma

Ombretta Annibali, Monica Di Cecca, Martina Verri, Mariantonietta Tafuri, Antonella Bianchi, Paolo Schiaroli, Valeria Tomarchio, Anna Crescenzi, Giuseppe Avvisati, Luigi Rigacci

Blood (2023) 142 (Supplement 1): 6607.

https://doi.org/10.1182/blood-2023-189171

Published: 2023

Journal Articles

Development of a Novel Prognostic Score in Patients with Waldenström Macroglobulinemia Prospectively Enrolled in the Observational NF10 Study of Fondazione Italiana Linfomi

Blood (2023) 142 (Supplement 1): 3046.

https://doi.org/10.1182/blood-2023-184586

Published: 2023

Journal Articles

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Blood (2023) 142 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2023-179922

Published: 2023

Journal Articles

Survival of Hodgkin Lymphoma Patients Treated with Novel Immunotherapies after Autologous Stem Cell Transplantation Failure: A Retrospective Analysis of the Italian Lymphoma Foundation (FIL)

Maura Nicolosi, Valentina Bozzoli, Sabino Ciavarella, Cattina Federica, Gloria Margiotta Casaluci, Ombretta Annibali, Alessia Castellino, Francesco Rotondo, Luigi Petrucci, Federica Cocito, Sofya Kovalchuk, Erika Meli, Natalia Cenfra, Sara Bigliardi, Angelo Fama, Stefano Volpetti, Barbara Botto, Benedetto Bruno, Francesco Zaja

Blood (2023) 142 (Supplement 1): 6219.

https://doi.org/10.1182/blood-2023-187563

Published: 2023

Journal Articles

Results of an Italian Retrospective Clinical Experience on Mediastinal Gray Zone Lymphoma

Blood (2023) 142 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2023-180036

Published: 2023

Journal Articles

Efficacy and Safety of Ibrutinib in Relapsed or Refractory Marginal Zone Lymphomas: The “Real World” Italian Experience

Blood (2023) 142 (Supplement 1): 1680.

https://doi.org/10.1182/blood-2023-182347

Published: 2023

Journal Articles

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Blood (2023) 142 (17): 1438–1447.

https://doi.org/10.1182/blood.2022019173

Published: 2023

Includes: Supplemental data

Journal Articles

Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi

Blood (2022) 140 (Supplement 1): 3603–3605.

https://doi.org/10.1182/blood-2022-166535

Published: 2022

Journal Articles

Clinical Features and Treatment Response in Patients with Multiple Myeloma and CD20 Expression: Real-Life Experience of the Centro-Italy Multiple Myeloma Macroregional District

Blood (2022) 140 (Supplement 1): 12549–12550.

https://doi.org/10.1182/blood-2022-166464

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy

Brentuximab vedotin (Bv)+AVD efficacy is influenced by interim PET, age, ECOG performance status and CIRS-g in previously untreated patients with stage IV classical Hodgkin lymphoma: An Italian real-life multicentric study

The treatment of transplant eligible primary plasmacell leukemia patients: An italian real-life Study

The prognostic value for survival of frailty and patient-reported outcomes in relapsed/refractory multiple myeloma: Results from a prospective multicenter observational study

Post-transplant lymphoproliferative disorders in adult transplant recipients: Preliminary results of the multicenter italian FIL_PTLD study

Lessons from the IELSG45 trial: The impact of patient fitness on dropout rate in primary central nervous system lymphoma (PCNSL) studies

Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi

Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study

Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Incidence of Infections and Prophylaxis Practice, in Two Cohorts of Patients of Autoimmune Disorders of Hematological Interest or Non-Hodgkin Lymphoma Treated with Rituximab

T Cell Ig and ITIM Domains (TIGIT) Expression in Multiple Myeloma

Development of a Novel Prognostic Score in Patients with Waldenström Macroglobulinemia Prospectively Enrolled in the Observational NF10 Study of Fondazione Italiana Linfomi

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Survival of Hodgkin Lymphoma Patients Treated with Novel Immunotherapies after Autologous Stem Cell Transplantation Failure: A Retrospective Analysis of the Italian Lymphoma Foundation (FIL)

Results of an Italian Retrospective Clinical Experience on Mediastinal Gray Zone Lymphoma

Efficacy and Safety of Ibrutinib in Relapsed or Refractory Marginal Zone Lymphomas: The “Real World” Italian Experience

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi

Clinical Features and Treatment Response in Patients with Multiple Myeloma and CD20 Expression: Real-Life Experience of the Centro-Italy Multiple Myeloma Macroregional District

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only